Market Overview

QIAGEN and Hamilton Launch New Collaboration to Improve Pre-Analytical Sample Processing for QuantiFERON-TB Gold Plus


Collaboration aims to accelerate adoption and ease of use in
processing single-tube sample collection version of the market-leading
modern blood test for latent TB detection

QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) and Hamilton
Robotics, a privately held leader in automation and liquid handling
technology, today announced a new collaboration to improve processing of
QIAGEN's QuantiFERON-TB Gold Plus (QFT-Plus) diagnostic test through the
integration of Hamilton's Microlab® STAR™ automated liquid
handling workstation into the QFT-Plus assay workflow. QIAGEN's
fourth-generation QuantiFERON-TB Gold Plus is the modern gold standard
for latent tuberculosis (TB) detection.

QuantiFERON-TB Gold Plus offers customers the most flexible workflow
among TB screening tests, including a single-tube option that enables
efficient screening in large-scale programs by collecting blood samples
at patient sites and transporting them to labs for processing up to 53
hours after venipuncture. Use of the Microlab STAR workstation will
standardize and automate the manual steps in liquid handling for those
samples, which can reduce hands-on time by 50% or more, provide greater
ease of use and ensure consistency in pre-analytic methods, reducing
processing errors and variability between runs.

"We are pleased to collaborate with Hamilton, a proven leader with a
track record of providing best-in-class liquid handling technology
solutions, to further improve the automation of our QuantiFERON-TB Gold
Plus test for customers," said Thierry Bernard, Senior Vice President,
Head of the Molecular Diagnostics Business Area at QIAGEN N.V. "This
integrated workflow, which has potential to be rolled out globally,
should significantly improve laboratories' economics and ease of use for
the QuantiFERON-TB technology, especially in clinical markets that
increasingly rely on the single-tube collection version of the test."

Michael Mouradian, Director of Robotics at Hamilton Robotics added, "Our
collaboration with QIAGEN puts the clinician and patient at center stage
when it comes to tuberculosis testing. With this hands-free automated
workflow, everyone can be confident that the next steps in patient care
are based on highly accurate and timely results."

Please find the full press release here

View Comments and Join the Discussion!